Home › Funds › Euclidean Capital LLC › ORIC
Euclidean Capital LLC position in ORIC
ORIC PHARMACEUTICALS INC · Health Care
Euclidean Capital LLC reported holding 989,410 shares of ORIC (ORIC PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$10.7M, representing 2.44% of its reported portfolio and ranking #4 among its reported holdings. Euclidean Capital LLC has disclosed ORIC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Euclidean Capital LLC's ORIC position evolved
Euclidean Capital LLC first disclosed a stake in ORIC in Q3 2023 at 989,410 shares (US$6.0M). The position peaked in Q1 2024 at 989,410 shares, worth US$13.6M. Across 12 filings, Euclidean Capital LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 989,410 shares valued at US$10.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 989.41K | $5.99M | New |
| Q4 2023 | 989.41K | $9.10M | Hold |
| Q1 2024 | 989.41K | $13.60M | Hold |
| Q2 2024 | 989.41K | $7.00M | Hold |
| Q3 2024 | 989.41K | $10.14M | Hold |
| Q4 2024 | 989.41K | $7.98M | Hold |
| Q1 2025 | 989.41K | $5.52M | Hold |
| Q2 2025 | 989.41K | $10.04M | Hold |
| Q3 2025 | 989.41K | $11.87M | Hold |
| Q4 2025 | 989.41K | $8.09M | Hold |
| Q1 2026 | 989.41K | $12.54M | Hold |
| Q2 2026 | 989.41K | $10.72M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ORIC and 13F data
ORIC (ORIC PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in ORIC — the largest reported positions include Nextech Invest Ltd. (US$77.6M), EcoR1 Capital, LLC (US$72.9M), SR ONE CAPITAL MANAGEMENT, LP (US$50.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ORIC
- Nextech Invest Ltd. 7.16M sh · $77.57M · Q2 2026
- EcoR1 Capital, LLC 6.73M sh · $72.87M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.62M sh · $49.98M · Q2 2026
- Venrock Adviser, LLC 4.32M sh · $46.78M · Q2 2026
- NEA Management Company, LLC 4.12M sh · $44.60M · Q2 2026
- AIHC Capital Management Ltd 3.83M sh · $41.46M · Q2 2026
- Column Group LLC 3.54M sh · $38.35M · Q2 2026
- Siren, L.L.C. 3.00M sh · $32.47M · Q2 2026
- First Turn Management, LLC 2.02M sh · $21.85M · Q2 2026
- Integral Health Asset Management, LLC 1.90M sh · $20.58M · Q2 2026
- MPM BioImpact LLC 1.88M sh · $20.38M · Q2 2026
- Vivo Capital, LLC 1.85M sh · $20.02M · Q2 2026
More on Euclidean Capital LLC
FAQ
How long has Euclidean Capital LLC held ORIC?
Euclidean Capital LLC has disclosed ORIC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Euclidean Capital LLC's current position in ORIC?
As of Q2 2026, Euclidean Capital LLC holds 989.41K shares of ORIC (ORIC PHARMACEUTICALS INC), valued at $10.72M, representing 2.44% of its reported portfolio and ranking #4.
Has Euclidean Capital LLC been buying or selling ORIC?
In the latest 13F filing (Q2 2026), Euclidean Capital LLC held unchanged its position in ORIC. The position peaked in Q1 2024 at 989.41K shares.
Which other funds hold ORIC?
Other major institutional holders of ORIC include Nextech Invest Ltd., EcoR1 Capital, LLC, SR ONE CAPITAL MANAGEMENT, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.